Holen Sie sich die Stockscreener-App
110.12
5.48%
-6.39
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum - Yahoo Finance
Palvella Therapeutics, Inc. Balance Sheet – LSX:A40RA6 - TradingView
ETFs Investing in Palvella Therapeutics, Inc. Stocks - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail
Return on invested capital % of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Cash Flow – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Earnings and Revenue – LS:A40RA6 - TradingView
CapEx per share of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Revenue per share of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Diluted net income available to common stockholders of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBITDA ratio of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Non-controlling/minority interest of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Balance Sheet – LS:A40RA6 - TradingView
Current ratio of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Statistics – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Dividends – LS:A40RA6 - TradingView
Discontinued operations of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Financial Statements – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Revenue Breakdown – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Income Statement – LS:A40RA6 - TradingView
Palvella Therapeutics (PVLA) price target increased by 33.50% to 178.50 - MSN
Palvella Therapeutics (PVLA) director receives 3,000 stock options grant - Stock Titan
Palvella Therapeutics (PVLA) director granted 3,000 stock options at $102.19 - Stock Titan
ResVita Bio adds dermatologist John Doux to board By Investing.com - Investing.com Nigeria
PVLA: All proposals, including board elections and equity plan amendment, were approved by majority vote - TradingView
PVLA: All proposals passed, including director elections and equity plan amendment; no questions submitted - TradingView
ResVita Bio adds dermatologist John Doux to board - Investing.com UK
PVLA: Positive phase III data, strong cash position, and expanding rare disease pipeline drive growth - TradingView
Dermatologist-investor John Doux joins ResVita Bio board - Stock Titan
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - Moomoo
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish - Seeking Alpha
Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin - Moomoo
Palvella completes pre-NDA meeting with FDA for rapamycin gel - Investing.com UK
The Prognosis For Palvella Therapeutics (NASDAQ:PVLA) - Seeking Alpha
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations - markets.businessinsider.com
Palvella completes pre-NDA meeting with FDA for rapamycin gel By Investing.com - Investing.com South Africa
Palvella Therapeutics Advances QTORIN™ Rapamycin Toward NDA Submission for Microcystic Lymphatic Malformations in 2026 - Quiver Quantitative
Potential first treatment for rare disorder on track for 2026 FDA filing - Stock Titan
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Mizuho Securities Sticks to Their Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics Secures Patent Extending QTORIN™ Pitavastatin Market Exclusivity to 2043 for PROS Treatment - geneonline.com
Palvella secures U.S. patent for porokeratosis treatment - Investing.com UK
Palvella secures U.S. patent for porokeratosis treatment By Investing.com - Investing.com South Africa
Palvella Therapeutics Announces Issuance of U.S. Patent for QTORIN™ Pitavastatin in Treatment of Porokeratosis, Including DSAP - Quiver Quantitative
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 - The Manila Times
Kathleen Goin, Palvella COO, sells $475,630 in company stock By Investing.com - Investing.com India
Kathleen Goin, Palvella COO, sells $475,630 in company stock - Investing.com
Number of shareholders of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):